EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Standardizing economic evaluation in Spain’s pharmaceutical pricing and reimbursement system: specification, interpretation and integration

Marta Trapero-Bertran iD

Expert Review of Pharmacoeconomics & Outcomes Research · 03.07.2026 · 26 (6) · 709-721

DOI: 10.1080/14737167.2026.2691179 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 22.06.2026. Verfasst von Marta Trapero-Bertran. Beteiligte Einrichtung: Economics and Business Department, Faculty of Law, Economics and Tourism (FDET), Universitat de Lleida, Igualada, Catalonia, Spain. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Reimbursement Mechanisms, Drug Costs, Economics, Pharmaceutical. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Economic evaluation (EE) is a key input for pharmaceutical pricing and reimbursement (P&R), yet countries differ in how EE is specified, interpreted and integrated into decisions. Spain is a timely case: despite long-standing legal recognition of efficiency, EE has historically been weakly operationalized and difficult to trace in P&R. AREAS COVERED: This narrative review analyses Spain's reform trajectory through the lenses of specification, interpretation and integration, focusing on the work of the Advisory Committee for Pharmaceutical Financing (CAPF) (2019-2024). Evidence was identified through searches in PubMed, Scopus, Web of Science and Google Scholar (2000-2025), complemented by Spanish and EU legislative and policy documents. The review synthesizes CAPF recommendations to reorganize the evaluation pathway, including structured model linking clinical assessment, EE and budget impact analysis, and publication of national guideline and reference case. It also examines how these initiatives interact with draft national reforms and the EU HTA Regulation, highlighting a hybrid transitional context (late 2025) in which Joint Clinical Assessments are progressively incorporated while national procedural reform remains incomplete. EXPERT OPINION: Spain illustrates how EE standardization can strengthen deliberative, multi-criteria P&R by improving transparency and coherence, although impact depends on regulatory enactment, capacity and implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalReimbursement MechanismsDrug CostsEconomics, PharmaceuticalSpainHumansAdvisory CommitteesCost-Benefit Analysis

Stichwörter der Autor:innen

Economic evaluationNational Health SystemSpainhealth technology assessmentpharmaceutical pricingreimbursementstandardized guidelines

Autor:innen und Institutionen

  • Economics and Business Department, Faculty of Law, Economics and Tourism (FDET), Universitat de Lleida, Igualada, Catalonia, Spain.

ORCID-Profile: Marta Trapero-Bertran

Zitieren

APA

Trapero-Bertran, M. (2026). Standardizing economic evaluation in Spain’s pharmaceutical pricing and reimbursement system: specification, interpretation and integration. Expert Review of Pharmacoeconomics & Outcomes Research, 26(6), 709-721. https://doi.org/10.1080/14737167.2026.2691179

Vancouver

Trapero-Bertran M. Standardizing economic evaluation in Spain’s pharmaceutical pricing and reimbursement system: specification, interpretation and integration. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(6):709-721. doi:10.1080/14737167.2026.2691179

BibTeX
@article{TraperoBertran2026,
  author = {Trapero-Bertran, Marta},
  title = {Standardizing economic evaluation in Spain’s pharmaceutical pricing and reimbursement system: specification, interpretation and integration},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {709--721},
  doi = {10.1080/14737167.2026.2691179}
}
Kostenlos starten →